Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TXA16126
- Development stage
- Preclinical
- Lead developer
- TAXIS Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TXA16126 is a small molecule dihydrofolate reductase (DHFR) inhibitor being developed by TAXIS Pharmaceuticals. It is currently in the lead optimization stage for the treatment of drug-resistant gonorrhea (often referred to as "Super Gonorrhea") and Chlamydia. The drug's mechanism of action involves the inhibition of bacterial DHFR, an enzyme essential for the synthesis of tetrahydrofolate, thereby disrupting bacterial folate metabolism and preventing DNA synthesis and cell growth. This program aims to address the growing clinical need for new antibiotics to treat multidrug-resistant sexually transmitted infections.
- Other names
- TXA16126TXA-16126TXA 16126
02
Targets
DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on TXA16126.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TXA16126.